Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Intratumoral heterogeneity as a predictive biomarker in anti-PD-(L)1 therapies for non-small cell lung cancer

23 Feb 2021

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Lung Cancer Treatments and Mutations
Share to Radiomics and Machine Learning in Medical Imaging

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 33622313
DOI: 10.1186/s12943-021-01331-9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Intratumoral heterogeneity as a predictive biomarker in anti-PD-(L)1 therapies for non-small cell lung cancerPMID 33622313Read ↗

The Role of Intratumor Heterogeneity in the Response of Metastatic Non-Small Cell Lung Cancer to Immune Checkpoint InhibitorsSemantic proximity Read ↗

Intratumoral Cellular Heterogeneity: Implications for Drug Resistance in Patients with Non-Small Cell Lung CancerSemantic proximity Read ↗

Intratumoral heterogeneity in cancer progression and response to immunotherapySemantic proximity Read ↗

Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancerSemantic proximity Read ↗

The role of molecular heterogeneity targeting resistance mechanisms to lung cancer therapiesSemantic proximity Read ↗

Intratumor Heterogeneity: The Rosetta Stone of Therapy Resistance.Semantic proximity Read ↗

Intratumor heterogeneity reflects clinical disease courseSemantic proximity Read ↗

Intrapatient variation in PD-L1 expression and tumor mutational burden and implications for outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer.Semantic proximity Read ↗

Multiregion gene expression profiling reveals heterogeneity in molecular subtypes and immunotherapy response signatures in lung cancer.Semantic proximity Read ↗

Intratumoral Heterogeneity: More Than Just MutationsSemantic proximity Read ↗

Spatial profiling of the microenvironment reveals low intratumoral heterogeneity and STK11-associated immune evasion in therapy-naïve lung adenocarcinomas.Semantic proximity Read ↗

[Intratumor heterogeneity, a Darwinian stumbling block towards personalized medicine?].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.